J&J Beats Earnings Estimates as Tremfya Sales Surge, Middle East Conflict Weighs on Devices

J&J reports Q3 revenue of $25.4B and adjusted EPS of $2.59, beating estimates. Tremfya sales surge 68% while Middle East conflict weighs on medical device results.